Elevated Serum Levels of CXC Chemokine Ligand-12 Are Associated with Unfavorable Functional Outcome and Mortality at 6-Month Follow-up in Chinese Patients with Acute Ischemic Stroke

Molecular Neurobiology

Volumn 54, Issue 2, 2017, Pages 895-903

  Cheng, Xuan ^a   Lian, Ya Jun ^a   Ma, Yun Qing ^a   Xie, Nan Chang ^a   Wu, Chuan Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Acute ischemic stroke; Chinese; CXC chemokine ligand 12; Functional outcome; Mortality

Indexed keywords

STROMAL CELL DERIVED FACTOR 1; BIOLOGICAL MARKER; CXCL12 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHINESE; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANKIN SCALE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; DIAGNOSTIC IMAGING; MIDDLE AGED; PHYSIOLOGY; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; BRAIN ISCHEMIA; CHEMOKINE CXCL12; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; STROKE; TIME FACTORS;

EID: 84954411602     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9645-9     Document Type: Article

References (44)

1. Bonita R, Mendis S, Truelsen T et al (2004) The global stroke initiative. Lancet Neurol 3:391–393
2. Song FY, Wu MH, Zhu LH et al (2015) Elevated serum mannose-binding lectin levels are associated with poor outcome after acute ischemic stroke in patients with type 2 diabetes. Mol Neurobiol 52(3):1330–1340
3. Zhang JL, Yin CH, Zhang Y et al (2013) Plasma copeptin and long term outcomes in acute ischemic stroke. Acta Neurol Scand 128:372–380
4. Iwamoto T, Okamoto H, Toyama Y et al (2008) Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 275:4448–4455
5. Schutt RC, Burdick MD, Strieter RM et al (2012) Plasma CXCL12 levels as a predictor of future stroke. Stroke 43:3382–3386
6. Nagasawa T (2014) CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med 92:433–439
7. Xu Q, Sun XC, Shang XP, Jiang HS (2012) Association of CXCL12 levels in synovial fluid with the radiographic severity of knee osteoarthritis. J Investig Med 60:898–901
8. Camnitz W, Burdick MD, Strieter RM et al (2012) Dose-dependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clin Transl Med 1:1–5
9. Karouzakis E, Rengel Y, Jüngel A et al (2011) DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 12:643–652
10. Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230
11. van den Berk LCJ, van der Veer A, Willemse ME et al (2013) Disturbed CXCR4/CXCL12 axis in pediatric precursor B-cell acute lymphoblastic leukemia. Blood 122:2643–2643
12. Saiman Y, Jiao JJ, Fiel MI et al (2015) Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury. Hepatol Res 45:794–803
13. Negrete-García MC, Velazquez JR, Popoca-Coyotl A et al (2010) Chemokine (CXC motif) ligand 12/stromal cell-derived factor-1 is associated with leukocyte recruitment in asthma. CHEST J 138:100–106
14. Li M, Hale JS, Rich JN et al (2012) Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci 35:619–628
15. Van Der Vorst E, Doering Y, Weber C (2015) MIF and CXCL12 in cardiovascular diseases: functional differences and similarities. Frontiers Immunol 6:373
16. Robin AM, Zhang ZG, Wang L, Zhang RL, Katakowski M, Zhang L et al (2006) Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab 26:125–134
17. Yu X, Chen D, Zhang Y, Wu X, Huang Z, Zhou H et al (2012) Over-expression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J Neurol Sci 316:141–149
18. Wurster T, Stellos K, Geisler T, Seizer P, Andia ME, Schuster A et al (2012) Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke? Eur J Neurol 19:395–401
19. Ruscher K, Kuric E, Liu Y et al (2013) Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J Cereb Blood Flow Metab 33:1225–1234
20. Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:541–553
21. Brott T, Adams HP Jr, Olinger CP et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870
22. Adams HP, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
23. Bamford J, Sandercock P, Dennis M et al (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526
24. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72:2104–2110
25. Zhang ZG, Wang C, Wang J, Zhang Z et al (2015) Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol 51:230–239
26. Guo Y, Apostalakis S, Blann AD, Lip GY (2014) Plasma CX3CL1 levels and long term outcomes of patients with atrial fibrillation: the West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 38:204–211
27. Gu XL, Liu L, Lu XD et al (2015) Serum CXCL12 levels as a novel predictor of future stroke recurrence in patients with acute ischemic stroke. Mol Neurobiol. doi:10.1007/s12035-015-9151-0
28. Mehta NN, Matthews G, Krishnamoorthy P et al (2012) Higher plasma CXCL12 levels predict incident cardiovascular disease events: findings from the Chronic Renal Insufficiency Cohort Study. Circulation 126(21 Supplement), A13352
29. Kim YS, Baek W, Kim K et al (2012) Association between serum stromal cell-derived factor-1α and long-term outcome of acute ischemic stroke. Eur Neurol 67:363–369
30. Kwon HS, Kim YS, Park HH et al (2015) Increased VEGF and decreased SDF-1α in patients with silent brain infarction are associated with better prognosis after first-ever acute lacunar stroke. J Stroke Cerebrovasc Dis 24:704–710
31. Duan XX, Zhang GP, Wang XB et al (2015) The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke. Neurol Sci 36:2227–2234
32. Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M et al (2011) A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 216:205–211
33. Liu P, Xiang JW, Jin SX (2015) Serum CXCL12 levels are associated with stroke severity and lesion volumes in stroke patients. Neurol Res 37:853–858
34. Bogoslovsky T, Spatz M, Chaudhry A, Maric D, Luby M, Frank J et al (2011) Stromal-derived factor-1α correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 42:618–625
35. Wang Y, Huang J, Li Y et al (2012) Roles of chemokine CXCL12 and its receptors in ischemic stroke. Curr Drug Targets 13:166–172
36. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28:299–307
37. Emsley HC, Tyrrell PJ (2002) Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 22:1399–1419
38. Li M, Ransohoff RM (2008) Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 84:116–131
39. Zernecke A, Bot I, Djalali-Talab Y et al (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102:209–217
40. van der Vorst EP, Döring Y, Weber C. (2015) Chemokines and their receptors in atherosclerosis. J Mol Med (Berl); Jul 15, DOI: 10.1007/s00109-015-1317-8.
41. Patel JR, McCandless EE, Dorsey D et al (2010) CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc Natl Acad Sci U S A 107:11062–11067
42. Mirabelli-Badenier M, Braunersreuther V, Viviani GL et al (2011) CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 105(3):409
43. Schönemeier B, Schulz S, Hoellt V et al (2008) Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol 198:39–45
44. Ardelt AA, Bhattacharyya BJ, Belmadani A et al (2013) Stromal derived growth factor-1 (CXCL12) modulates synaptic transmission to immature neurons during post-ischemic cerebral repair. Exp Neurol 248:246–253